Annals of Internal Medicine, 101(6), 891-891, 1984
The Premenstrual Syndrome and Progesterone Therapy
Author affiliations
- University College Hospital ROR
Abstract not indexed. Read at source
Topics
Dalton K premenstrual syndrome progesterone therapy, progesterone treatment PMS premenstrual syndrome review, premenstrual syndrome hormonal therapy progesterone supplementation, Dalton progesterone deficiency PMS clinical management, luteal phase progesterone premenstrual symptoms treatment, premenstrual syndrome pathophysiology progesterone therapy 1984, PMS progesterone replacement therapy efficacy evidence, cyclical progesterone premenstrual tension syndrome, hormonal treatment premenstrual syndrome Annals Internal Medicine
DOI 10.7326/0003-4819-101-6-891_1 10.7326/0003-4819-101-6-891_1
Cite this article
Dalton, K. (1984). The Premenstrual Syndrome and Progesterone Therapy. Annals of Internal Medicine, 101(6), 891-891. https://doi.org/10.7326/0003-4819-101-6-891_1
Dalton K. The Premenstrual Syndrome and Progesterone Therapy. Ann Intern Med. 1984;101(6):891-891. doi:10.7326/0003-4819-101-6-891_1
Dalton, K. "The Premenstrual Syndrome and Progesterone Therapy." Annals of Internal Medicine, vol. 101, no. 6, 1984, pp. 891-891.
Related articles
Perimenopause/MenopauseOvarian AgingPituitary-Ovarian AxisProgesterone Deficiency
Ovarian aging and the perimenopausal transition: the paradox of endogenous ovarian hyperstimulation
Prior JC, 2005·Endocrine
The purpose of this review is to put into a useful clinical context the changing over time of basic ovarian-pituitary-hypothalamic relationships during perimenopause. "Perimenopause" means changes in ovarian hormones, feedback relationships, and clinical experiences beginning in women ages 35-50 with regular flow and ending 1 yr after the final menstrual flow. A key observation must be explained--estradiol levels are increased in perimenopause. Inhibin B levels are lower and activin may be higher in midlife, menstruating women. These changes probably cause higher follicular phase FSH levels--"endogenous ovarian hyperstimulation" results. The positive estradiol feedback on LH is also disturbed--midcycle LH peaks and mid-luteal slow-frequency, high-amplitude LH pulses are less frequent. In addition to higher levels, estradiol receptors may increase in tissues of symptomatic women. Despite hyperstimulation of follicles, progesterone levels and luteal phase lengths are paradoxically decreased--reasons probably include LH peak disruptions and estrogen-stimulated greater corticotrophin-mediated reproductive suppression. In summary, disturbed feedback relationships causing higher and unpredictable estrogen and lower progesterone levels occur throughout perimenopause, especially during regular cycles. Prospective, population-based research is needed to systematically relate these feedback hormonal changes to clinical characteristics and to allow a diagnosis of perimenopause in regularly cycling midlife women.
Women's HealthEndometrial Cancer Risk and DetectionBreast Cancer Hormonal AssociationsOvarian Cancer Early Detection
Chapter 34: Cancer: NaProTECHNOLOGY and Early Detection
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Chapter 34 of Hilgers (2004) examines how NaProTechnology cycle charting may identify women at elevated risk endometrial, breast, and ovarian. The chapter presents clinical case series and a small prospective study suggesting that observable cycle biomarkers, particularly patterns indicating suboptimal luteal-phase function, may precede diagnosis and could inform earlier evaluation, while calling explicitly for further research to validate these findings.
Menstrual CycleProgesterone TreatmentTherapeutic UseCrossover Design
Ineffectiveness of progesterone suppository treatment for premenstrual syndrome
Freeman E et al., 1990·JAMA
Progesterone is the most widely used treatment for premenstrual syndrome. To answer definitely the question of whether progesterone suppositories are effective for the treatment of premenstrual syndrome, a randomized, placebo-controlled, double-blind crossover study of 168 women, receiving progesterone in doses of 400 and 800 mg or placebo, was carried out. Premenstrual symptoms were not significantly improved by progesterone compared with placebo in any measure used in the study, including daily symptom reports maintained throughout treatment, clinician evaluation of improvement, and patient global reports of symptoms severity, relief, and disruption of daily activity. No symptom cluster or individual symptom differed significantly between progesterone and placebo treatment. These treatment results were not significantly affected by fluctuations in response during the placebo washout period, pretreatment levels of depression or anxiety at either postmenstrual or premenstrual times, or any of 19 other background, medical history, or symptom variables examined individually as covariates with treatment.
Reproductive EndocrinologyHormone MetabolismT3 T4 InterpretationThyroid Disorders
Thyroidal and peripheral production of thyroid hormones. Review of recent findings and their clinical implications
Schimmel M et al., 1977·Ann Intern Med
There are two biologically active thyroid hormones, thyroxine (T4) and triiodothyronine (T3). Most T3 is produced extrathyroidally, so that alterations in circulating thyroid hormone concentrations may occur as a result of both thyroidal and extrathyroidal abnormalities. Extrathyroidal T4 conversion to T3 is decreased in patients with different acute and chronic illnesses. When T4 conversion to T3 is impaired and serum T3 concentrations decline, serum concentrations of biologically inactive 3,3',5'-triiodothyronine (reverse T3) increase. In this review, we present current information on thyroidal and extrathyroidal T4 and T3 production in normal subjects and patients with various thyroid diseases and other illnesses, consider the physiologic significance of these changes, and discuss the value and interpretation of various iodothyronine measurements.